SIA
MYGN icon

Stancorp Investment Advisers’s Myriad Genetics MYGN Stock Holding History

Stancorp Investment Advisers’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$43K Hold
1,213
– – 0.02% 297
2014
Q4 		$41K Buy
+1,213
New +$43K 0.02% 278

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stancorp Investment Advisers's MYGN Position: Q1 2015 in Review

Stancorp Investment Advisers held its Myriad Genetics (MYGN) position steady in Q1 2015 at 1,213 shares worth $43K. The position accounts for 0.02% of the portfolio, ranked #297.

Stancorp Investment Advisers first reported a position in MYGN in Q4 2014 and has held it in 2 quarters since. 251 funds tracked by Wall St. Rank hold MYGN as of Q1 2015.

  • Stancorp Investment Advisers held 1,213 shares of Myriad Genetics worth $43K as of Q1 2015.
  • Stancorp Investment Advisers left its Myriad Genetics share count unchanged in Q1 2015.
  • Myriad Genetics made up 0.02% of Stancorp Investment Advisers's portfolio in Q1 2015, its #297 holding.
  • Stancorp Investment Advisers first reported a position in Myriad Genetics in Q4 2014 and has held it in 2 quarters since.
  • 251 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2015.

Based on Stancorp Investment Advisers's 13F filing for Q1 2015, filed 13 May 2015.